Live from CCOLD: Dr Davids Discusses the ALPINE Trial in CLL

In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the results of the ALPINE trial with Dr. Matthew Davies. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. In this episode, Dr. Davids discusses the impact of the results of the ALPINE trial for clinical practice given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory CLL and SLL.Our Guest:Dr Davids is the Director of Clinical Research at the Division of Lymphoma at the Dana Farber Institute and Associate Professor of Medicine at Harvard Medical School. Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.This podcast episode was sponsored by BeiGene Canada ULC.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com